Attachment inhibitor may hold promise for future. BMS-488043 demonstrates safety.
Bristol-Myers Squibb Co. recently showed through concept data that an attachment inhibitor BMS-488043 can have potent antiviral activity in HIV-1-infected patients.
D017322:Clinical Trials, Phase II as Topic; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010919:Placebos; D019562:Viral Load
D023581:HIV Fusion Inhibitors; D010919:Placebos